Bibliografías temáticas / Metal-based drugs / Artículos de revistas
Siga este enlace para ver otros tipos de publicaciones sobre el tema: Metal-based drugs.

Artículos de revistas sobre el tema "Metal-based drugs"

Autor: Grafiati
Publicado: 10 de marzo de 2023

Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros

Elija tipo de fuente:

Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "Metal-based drugs".

Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.

También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.

Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.

1

Mcquitty, Ruth J. "Metal-based Drugs". Science Progress 97, n.º 1 (marzo de 2014): 1–19. http://dx.doi.org/10.3184/003685014x13898980185076.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

Dyson, Paul J. "Metal-based Drugs". Australian Journal of Chemistry 63, n.º 11 (2010): 1503. http://dx.doi.org/10.1071/ch10382.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

Benjamin Garbutcheon-Singh, K., Maxine P. Grant, Benjamin W. Harper, Anwen M. Krause-Heuer, Madhura Manohar, Nikita Orkey y Janice R. Aldrich-Wright. "Transition Metal Based Anticancer Drugs". Current Topics in Medicinal Chemistry 11, n.º 5 (1 de marzo de 2011): 521–42. http://dx.doi.org/10.2174/156802611794785226.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
4

Sava, Gianni. "Metal Based Drugs Restyled and Resumed". Metal-Based Drugs 2007 (25 de marzo de 2007): 1. http://dx.doi.org/10.1155/2007/16260.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
5

Timerbaev, Andrei R. y Bernhard K. Keppler. "Capillary electrophoresis of metal-based drugs". Analytical Biochemistry 369, n.º 1 (octubre de 2007): 1–7. http://dx.doi.org/10.1016/j.ab.2007.05.009.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
6

Vlasiou, Manos. "In Search of Antiviral Metal-Based Drugs". Open Medicinal Chemistry Journal 15, n.º 1 (31 de diciembre de 2021): 30–31. http://dx.doi.org/10.2174/1874104502015010030.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
7

Allardyce, Claire S. y Paul J. Dyson. "Metal-based drugs that break the rules". Dalton Transactions 45, n.º 8 (2016): 3201–9. http://dx.doi.org/10.1039/c5dt03919c.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
8

Fricker, Simon Paul. "Metal based drugs: from serendipity to design". Dalton Transactions, n.º 43 (2007): 4903. http://dx.doi.org/10.1039/b705551j.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
9

Aderibigbe, B. A. "Polymeric Prodrugs Containing Metal-Based Anticancer Drugs". Journal of Inorganic and Organometallic Polymers and Materials 25, n.º 3 (4 de abril de 2015): 339–53. http://dx.doi.org/10.1007/s10904-015-0220-7.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
10

Reisner, Erwin, Vladimir B. Arion, Bernhard K. Keppler y Armando J. L. Pombeiro. "Electron-transfer activated metal-based anticancer drugs". Inorganica Chimica Acta 361, n.º 6 (mayo de 2008): 1569–83. http://dx.doi.org/10.1016/j.ica.2006.12.005.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
11

Jia, Shuailong, Runjing Wang, Kui Wu, Hongliang Jiang y Zhifeng Du. "Elucidation of the Mechanism of Action for Metal Based Anticancer Drugs by Mass Spectrometry-Based Quantitative Proteomics". Molecules 24, n.º 3 (6 de febrero de 2019): 581. http://dx.doi.org/10.3390/molecules24030581.

Texto completo
Resumen
The discovery of the anticancer activity of cisplatin and its clinical application has opened a new field for studying metal-coordinated anticancer drugs. Metal-based anticancer drugs, such as cisplatin, can be transported to cells after entering into the human body and form metal–DNA or metal–protein adducts. Then, responding proteins will recognize adducts and form stable complexes. The proteins that were binding with metal-based anticancer drugs were relevant to their mechanism of action. Herein, investigation of the recognition between metal-based anticancer drugs and its binding partners will further our understanding about the pharmacology of cytotoxic anticancer drugs and help optimize the structure of anticancer drugs. The “soft” ionization mass spectrometric methods have many advantages such as high sensitivity and low sample consumption, which are suitable for the analyses of complex biological samples. Thus, MS has become a powerful tool for the identification of proteins binding or responding to metal-based anticancer drugs. In this review, we focused on the mass spectrometry-based quantitative strategy for the identification of proteins specifically responding or binding to metal-based anticancer drugs, ultimately elucidating their mechanism of action.
Los estilos APA, Harvard, Vancouver, ISO, etc.
12

Wang, Yi, Huaiyi Huang, Qianling Zhang y Pingyu Zhang. "Chirality in metal-based anticancer agents". Dalton Transactions 47, n.º 12 (2018): 4017–26. http://dx.doi.org/10.1039/c8dt00089a.

Texto completo
Resumen
Chiral metal-based drugs are currently an interesting and rapidly growing field in anticancer research. Here the different chiral metal-based anticancer agents and the extent to which the chiral resolution affects their biological properties are discussed. This review will aid the design of new potent and efficient chiral metal-based anticancer drugs that exploit the unique properties combined with their potential selectivity toward targeted chiral biomolecules.
Los estilos APA, Harvard, Vancouver, ISO, etc.
13

Levina, Aviva y Peter A. Lay. "Metal-based anti-diabetic drugs: advances and challenges". Dalton Transactions 40, n.º 44 (2011): 11675. http://dx.doi.org/10.1039/c1dt10380f.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
14

Fricker, Simon P. "Cysteine proteases as targets for metal-based drugs". Metallomics 2, n.º 6 (2010): 366. http://dx.doi.org/10.1039/b924677k.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
15

Abate, Chiara, Federica Carnamucio, Ottavia Giuffrè y Claudia Foti. "Metal-Based Compounds in Antiviral Therapy". Biomolecules 12, n.º 7 (3 de julio de 2022): 933. http://dx.doi.org/10.3390/biom12070933.

Texto completo
Resumen
In recent years, the study of metal complexes and metal-based nanomaterials has aroused particular interest, leading to the promotion of new effective systems for the abatement of various viral diseases. Starting from the analysis of chemical properties, this review focuses on the employment of metal-based nanoparticles as antiviral drugs and how this interaction leads to a substantial enhancement in antiviral activity. The use of metal-based antiviral drugs has also spread for the formulation of antiviral vaccines, thanks especially to the remarkable adjuvant activities of some of the metal complexes. In particular, the small size and inert nature of Au- and Ag-based nanoparticles have been exploited for the design of systems for antiviral drug delivery, leading to the development of specific and safe therapies that lead to a decrease in side effects.
Los estilos APA, Harvard, Vancouver, ISO, etc.
16

Wang, Ying y Jen-Fu Chiu. "Proteomic Approaches in Understanding Action Mechanisms of Metal-Based Anticancer Drugs". Metal-Based Drugs 2008 (22 de julio de 2008): 1–9. http://dx.doi.org/10.1155/2008/716329.

Texto completo
Resumen
Medicinal inorganic chemistry has been stimulating largely by the success of the anticancer drug, cisplatin. Various metal complexes are currently used as therapeutic agents (e.g., Pt, Au, and Ru) in the treatment of malignant diseases, including several types of cancers. Understanding the mechanism of action of these metal-based drugs is for the design of more effective drugs. Proteomic approaches combined with other biochemical methods can provide comprehensive understanding of responses that are involved in metal-based anticancer drugs-induced cell death, including insights into cytotoxic effects of metal-based anticancer drugs, correlation of protein alterations to drug targets, and prediction of drug resistance and toxicity. This information, when coupled with clinical data, can provide rational basses for the future design and modification of present used metal-based anticancer drugs.
Los estilos APA, Harvard, Vancouver, ISO, etc.
17

De Castro, Federica, Michele Benedetti, Laura Del Coco y Francesco Paolo Fanizzi. "NMR-Based Metabolomics in Metal-Based Drug Research". Molecules 24, n.º 12 (15 de junio de 2019): 2240. http://dx.doi.org/10.3390/molecules24122240.

Texto completo
Resumen
Thanks to recent advances in analytical technologies and statistical capabilities, the application field of metabolomics has increased significantly. Currently, this approach is used to investigate biological substrates looking for metabolic profile alterations, diseases markers, and drug effects. In particular, NMR spectroscopy has shown great potential as a detection technique, mainly for the ability to detect multiple (10s to 100s) metabolites at once without separation. Only in recent years has the NMR-based metabolomic approach been extended to investigate the cell metabolic alterations induced by metal-based antitumor drug administration. As expected, these studies are mainly focused on platinum complexes, but some palladium and ruthenium compounds are also under investigation. The use of a metabolomics approach was very effective in assessing tumor response to drugs and providing insights into the mechanism of action and resistance. Therefore, metabolomics may open new perspectives into the development of metal-based drugs. In particular, it has been shown that NMR-based, in vitro metabolomics is a powerful tool for detecting variations of the cell metabolites induced by the metal drug exposure, thus offering also the possibility of identifying specific markers for in vivo monitoring of tumor responsiveness to anticancer treatments.
Los estilos APA, Harvard, Vancouver, ISO, etc.
18

Dyson, Paul J. y Gianni Sava. "Metal-based antitumour drugs in the post genomic era". Dalton Transactions, n.º 16 (2006): 1929. http://dx.doi.org/10.1039/b601840h.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
19

Yu, Yingjie, Quan Xu, Shasha He, Hejian Xiong, Qingfei Zhang, Weiguo Xu, Vincent Ricotta et al. "Recent advances in delivery of photosensitive metal-based drugs". Coordination Chemistry Reviews 387 (mayo de 2019): 154–79. http://dx.doi.org/10.1016/j.ccr.2019.01.020.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
20

Skos, Lukas, Yasmin Borutzki, Christopher Gerner y Samuel M. Meier-Menches. "Methods to identify protein targets of metal-based drugs". Current Opinion in Chemical Biology 73 (abril de 2023): 102257. http://dx.doi.org/10.1016/j.cbpa.2022.102257.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
21

Cirri, Damiano, Francesco Bartoli, Alessandro Pratesi, Emma Baglini, Elisabetta Barresi y Tiziano Marzo. "Strategies for the Improvement of Metal-Based Chemotherapeutic Treatments". Biomedicines 9, n.º 5 (4 de mayo de 2021): 504. http://dx.doi.org/10.3390/biomedicines9050504.

Texto completo
Resumen
This article provides an overview of the various research approaches we have explored in recent years to improve metal-based agents for cancer or infection treatments. Although cisplatin, carboplatin, and oxaliplatin remain the cornerstones in tumor chemotherapy, the discovery and approval of novel inorganic anticancer drugs is a very slow process. Analogously, although a few promising inorganic drugs have found clinical application against parasitic or bacterial infections, their use remains relatively limited. Moreover, the discovery process is often affected by small therapeutic enhancements that are not attractive for the pharmaceutical industry. However, the availability of increasing mechanistic information for the modes of action of established inorganic drugs is fueling the exploration of various approaches for developing effective inorganic chemotherapy agents. Through a series of examples, some from our own research experience, we focus our attention on a number of promising strategies, including (1) drug repurposing, (2) the simple modification of the chemical structures of approved metal-based drugs, (3) testing novel drug combinations, and (4) newly synthesized complexes coupling different anticancer drugs. Accordingly, we aim to suggest and summarize a series of reliable approaches that are exploitable for the development of improved and innovative treatments.
Los estilos APA, Harvard, Vancouver, ISO, etc.
22

Claudel, Mickaël, Justine V. Schwarte y Katharina M. Fromm. "New Antimicrobial Strategies Based on Metal Complexes". Chemistry 2, n.º 4 (16 de octubre de 2020): 849–99. http://dx.doi.org/10.3390/chemistry2040056.

Texto completo
Resumen
Traditional organic antimicrobials mainly act on specific biochemical processes such as replication, transcription and translation. However, the emergence and wide spread of microbial resistance is a growing threat for human beings. Therefore, it is highly necessary to design strategies for the development of new drugs in order to target multiple cellular processes that should improve their efficiency against several microorganisms, including bacteria, viruses or fungi. The present review is focused on recent advances and findings of new antimicrobial strategies based on metal complexes. Recent studies indicate that some metal ions cause different types of damages to microbial cells as a result of membrane degradation, protein dysfunction and oxidative stress. These unique modes of action, combined with the wide range of three-dimensional geometries that metal complexes can adopt, make them suitable for the development of new antimicrobial drugs.
Los estilos APA, Harvard, Vancouver, ISO, etc.
23

Yang, Junlei, Lihuan Yue, Zhu Yang, Yuqing Miao, Ruizhuo Ouyang y Yihong Hu. "Metal-Based Nanomaterials: Work as Drugs and Carriers against Viral Infections". Nanomaterials 11, n.º 8 (20 de agosto de 2021): 2129. http://dx.doi.org/10.3390/nano11082129.

Texto completo
Resumen
Virus infection is one of the threats to the health of organisms, and finding suitable antiviral agents is one of the main tasks of current researchers. Metal ions participate in multiple key reaction stages of organisms and maintain the important homeostasis of organisms. The application of synthetic metal-based nanomaterials as an antiviral therapy is a promising new research direction. Based on the application of synthetic metal-based nanomaterials in antiviral therapy, we summarize the research progress of metal-based nanomaterials in recent years. This review analyzes the three inhibition pathways of metal nanomaterials as antiviral therapeutic materials against viral infections, including direct inactivation, inhibition of virus adsorption and entry, and intracellular virus suppression; it further classifies and summarizes them according to their inhibition mechanisms. In addition, the use of metal nanomaterials as antiviral drug carriers and vaccine adjuvants is summarized. The analysis clarifies the antiviral mechanism of metal nanomaterials and broadens the application in the field of antiviral therapy.
Los estilos APA, Harvard, Vancouver, ISO, etc.
24

Ringhieri, Paola, Giancarlo Morelli y Antonella Accardo. "Supramolecular Delivery Systems for Non-Platinum Metal-Based Anticancer Drugs". Critical Reviews™ in Therapeutic Drug Carrier Systems 34, n.º 2 (2017): 149–83. http://dx.doi.org/10.1615/critrevtherdrugcarriersyst.2017016936.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
25

Shahandeh, B., D. F. Brayton, J. Midyett y P. J. Farmer. "Synthesis and design of metal based drugs targeting melanoma cancer." Pigment Cell Research 17, n.º 4 (agosto de 2004): 451. http://dx.doi.org/10.1111/j.1600-0749.2004.00175_78.x.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
26

Odani, Akira y Hiromu Sakurai. "Frontier of the Research and Development of Metal-based Drugs". YAKUGAKU ZASSHI 132, n.º 3 (1 de marzo de 2012): 251. http://dx.doi.org/10.1248/yakushi.132.251.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
27

Elder, Richard C. y Marly K. Eidsness. "Synchrotron x-ray studies of metal-based drugs and metabolites". Chemical Reviews 87, n.º 5 (octubre de 1987): 1027–46. http://dx.doi.org/10.1021/cr00081a008.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
28

Ferraro, Maria Grazia, Marialuisa Piccolo, Gabriella Misso, Rita Santamaria y Carlo Irace. "Bioactivity and Development of Small Non-Platinum Metal-Based Chemotherapeutics". Pharmaceutics 14, n.º 5 (28 de abril de 2022): 954. http://dx.doi.org/10.3390/pharmaceutics14050954.

Texto completo
Resumen
Countless expectations converge in the multidisciplinary endeavour for the search and development of effective and safe drugs in fighting cancer. Although they still embody a minority of the pharmacological agents currently in clinical use, metal-based complexes have great yet unexplored potential, which probably hides forthcoming anticancer drugs. Following the historical success of cisplatin and congeners, but also taking advantage of conventional chemotherapy limitations that emerged with applications in the clinic, the design and development of non-platinum metal-based chemotherapeutics, either as drugs or prodrugs, represents a rapidly evolving field wherein candidate compounds can be fine-tuned to access interactions with druggable biological targets. Moving in this direction, over the last few decades platinum family metals, e.g., ruthenium and palladium, have been largely proposed. Indeed, transition metals and molecular platforms where they originate are endowed with unique chemical and biological features based on, but not limited to, redox activity and coordination geometries, as well as ligand selection (including their inherent reactivity and bioactivity). Herein, current applications and progress in metal-based chemoth are reviewed. Converging on the recent literature, new attractive chemotherapeutics based on transition metals other than platinum—and their bioactivity and mechanisms of action—are examined and discussed. A special focus is committed to anticancer agents based on ruthenium, palladium, rhodium, and iridium, but also to gold derivatives, for which more experimental data are nowadays available. Next to platinum-based agents, ruthenium-based candidate drugs were the first to reach the stage of clinical evaluation in humans, opening new scenarios for the development of alternative chemotherapeutic options to treat cancer.
Los estilos APA, Harvard, Vancouver, ISO, etc.
29

Renfrew, AnnaK. "Spectroscopic Approaches to Tracking Metal-based Drugs in Cells and Tissue". CHIMIA International Journal for Chemistry 71, n.º 3 (29 de marzo de 2017): 112–19. http://dx.doi.org/10.2533/chimia.2017.112.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
30

Zitka, Ondrej, Marketa Ryvolova, Jaromir Hubalek, Tomas Eckschlager, Vojtech Adam y Rene Kizek. "From Amino Acids to Proteins as Targets for Metal-based Drugs". Current Drug Metabolism 13, n.º 3 (1 de marzo de 2012): 306–20. http://dx.doi.org/10.2174/138920012799320437.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
31

Bertrand, Benoît, Pierre-Emmanuel Doulain, Christine Goze y Ewen Bodio. "Development of trackable metal-based drugs: new generation of therapeutic agents". Dalton Transactions 45, n.º 33 (2016): 13005–11. http://dx.doi.org/10.1039/c5dt04275e.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
32

Kandioller, Wolfgang, Andrea Kurzwernhart, Muhammad Hanif, Samuel M. Meier, Helena Henke, Bernhard K. Keppler y Christian G. Hartinger. "Pyrone derivatives and metals: From natural products to metal-based drugs". Journal of Organometallic Chemistry 696, n.º 5 (marzo de 2011): 999–1010. http://dx.doi.org/10.1016/j.jorganchem.2010.11.010.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
33

Amolegbe, Saliu A., Caroline A. Akinremi, Sheriff Adewuyi, Amudat Lawal, Mercy O. Bamigboye y Joshua A. Obaleye. "Some nontoxic metal-based drugs for selected prevalent tropical pathogenic diseases". JBIC Journal of Biological Inorganic Chemistry 22, n.º 1 (30 de noviembre de 2016): 1–18. http://dx.doi.org/10.1007/s00775-016-1421-4.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
34

Boros, Eszter, Paul J. Dyson y Gilles Gasser. "Classification of Metal-Based Drugs according to Their Mechanisms of Action". Chem 6, n.º 1 (enero de 2020): 41–60. http://dx.doi.org/10.1016/j.chempr.2019.10.013.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
35

Lainé, Anne-Laure y Catherine Passirani. "Novel metal-based anticancer drugs: a new challenge in drug delivery". Current Opinion in Pharmacology 12, n.º 4 (agosto de 2012): 420–26. http://dx.doi.org/10.1016/j.coph.2012.04.006.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
36

Todorov, Lozan y Irena Kostova. "Recent Trends in the Development of Novel Metal-Based Antineoplastic Drugs". Molecules 28, n.º 4 (18 de febrero de 2023): 1959. http://dx.doi.org/10.3390/molecules28041959.

Texto completo
Resumen
Since the accidental discovery of the anticancer properties of cisplatin more than half a century ago, significant efforts by the broad scientific community have been and are currently being invested into the search for metal complexes with antitumor activity. Coordination compounds of transition metals such as platinum (Pt), ruthenium (Ru) and gold (Au) have proven their effectiveness as diagnostic and/or antiproliferative agents. In recent years, experimental work on the potential applications of elements including lanthanum (La) and the post-transition metal gallium (Ga) in the field of oncology has been gaining traction. The authors of the present review article aim to help the reader “catch up” with some of the latest developments in the vast subject of coordination compounds in oncology. Herewith is offered a review of the published scientific literature on anticancer coordination compounds of Pt, Ru, Au, Ga and La that has been released over the past three years with the hope readers find the following article informative and helpful.
Los estilos APA, Harvard, Vancouver, ISO, etc.
37

Mari, Matteo, Debora Carrozza, Gianluca Malavasi, Ettore Venturi, Giulia Avino, Pier Cesare Capponi, Michele Iori et al. "Curcumin-Based β-Diketo Ligands for Ga3+: Thermodynamic Investigation of Potential Metal-Based Drugs". Pharmaceuticals 15, n.º 7 (12 de julio de 2022): 854. http://dx.doi.org/10.3390/ph15070854.

Texto completo
Resumen
Curcumin is known for its therapeutic properties; among these, antioxidant, anti-inflammatory and anti-cancer ones stand out. Besides, curcumin metal complexes have shown widespread application in medicine and can be exploited as lead structures for developing metal-based drugs. Unfortunately, curcumin is poorly bioavailable, mainly due to its instability in physiological conditions; this weakness is tightly connected to the presence of the β-diketo moiety undergoing tautomeric equilibrium. Stability and metal-chelating ability can be tuned by modulating the electronic effects and steric hindrance close to the β-diketo moiety; in addition, formation of a metal complex shifts the tautomeric equilibrium towards the β-keto–enol form and increases stability in biological media. Among the metals used in clinical therapy, gallium nitrate has shown to have significant antitumor activity against non-Hodgkin lymphoma and bladder cancer, thus indicating that gallium-based drugs have potential for further development as antineoplastic agents with improved therapeutic activity. Curcuminoids have demonstrated high affinity for gallium(III), allowing the formation of stable positively charged M:L 1:2 β-diketonate complexes that benefit from the therapeutic activity of both the metal and the ligand. Seven new curcumin derivatives were synthesized and completely characterized. The new derivatives retain the solvent-dependent keto–enol tautomerism, with the prevalence of the diketo form in aqueous solution. Enhanced stability in simulated physiological conditions was observed in comparison to the lead compound curcumin. The presence of Ga3+ anticipates the dissociation of the enolic proton, allowing chelate complex formation, and simultaneously it shifts the tautomeric equilibrium towards the keto–enol form. A complete 1H/13C NMR and UV–Vis study was performed to define the metal-to-ligand stoichiometry ratio and the overall stability constants. In addition, we demonstrated that some of the derivatives have increased antiproliferative activity on colon cancer cells compared to curcumin and antioxidant properties. On the whole, the synthesized curcumin-based molecules may act as new gallium(III) chelators with improved stability with respect to curcumin and could open interesting perspectives for the development of novel therapeutic agents for cancer.
Los estilos APA, Harvard, Vancouver, ISO, etc.
38

Levina, Aviva, Debbie Crans y Peter Lay. "Advantageous Reactivity of Unstable Metal Complexes: Potential Applications of Metal-Based Anticancer Drugs for Intratumoral Injections". Pharmaceutics 14, n.º 4 (4 de abril de 2022): 790. http://dx.doi.org/10.3390/pharmaceutics14040790.

Texto completo
Resumen
Injections of highly cytotoxic or immunomodulating drugs directly into the inoperable tumor is a procedure that is increasingly applied in the clinic and uses established Pt-based drugs. It is advantageous for less stable anticancer metal complexes that fail administration by the standard intravenous route. Such hydrophobic metal-containing complexes are rapidly taken up into cancer cells and cause cell death, while the release of their relatively non-toxic decomposition products into the blood has low systemic toxicity and, in some cases, may even be beneficial. This concept was recently proposed for V(V) complexes with hydrophobic organic ligands, but it can potentially be applied to other metal complexes, such as Ti(IV), Ga(III) and Ru(III) complexes, some of which were previously unsuccessful in human clinical trials when administered via intravenous injections. The potential beneficial effects include antidiabetic, neuroprotective and tissue-regenerating activities for V(V/IV); antimicrobial activities for Ga(III); and antimetastatic and potentially immunogenic activities for Ru(III). Utilizing organic ligands with limited stability under biological conditions, such as Schiff bases, further enhances the tuning of the reactivities of the metal complexes under the conditions of intratumoral injections. However, nanocarrier formulations are likely to be required for the delivery of unstable metal complexes into the tumor.
Los estilos APA, Harvard, Vancouver, ISO, etc.
39

Saddam Hossain, Md. "Isoniazid Containing Metal Based Drugs as Potential Antimicrobial Agent: A Short Review". Science Journal of Chemistry 5, n.º 5 (2017): 62. http://dx.doi.org/10.11648/j.sjc.20170505.11.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
40

Bergamo, Alberta y Gianni Sava. "Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs". Dalton Transactions 40, n.º 31 (2011): 7817. http://dx.doi.org/10.1039/c0dt01816c.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
41

Ruiz-Ramírez, L., M. E. de la Rosa, I. Gracia-Mora, A. Mendoza, G. Pérez, G. Ferrer-Sueta, A. Tovar et al. "Casiopeinas, metal-based drugs a new class of antineoplastic and genotoxic compounds". Journal of Inorganic Biochemistry 59, n.º 2-3 (agosto de 1995): 207. http://dx.doi.org/10.1016/0162-0134(95)97313-f.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
42

Sava, Gianni, Alberta Bergamo y Paul J. Dyson. "Metal-based antitumour drugs in the post-genomic era: what comes next?" Dalton Transactions 40, n.º 36 (2011): 9069. http://dx.doi.org/10.1039/c1dt10522a.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
43

Ebrahimi, Hossein Pasha, Jabbar S. Hadi, Abdulelah A. Almayah, Zeinab Bolandnazar, Ali G. Swadi y Amirpasha Ebrahimi. "Metal-based biologically active azoles and β-lactams derived from sulfa drugs". Bioorganic & Medicinal Chemistry 24, n.º 5 (marzo de 2016): 1121–31. http://dx.doi.org/10.1016/j.bmc.2016.01.041.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
44

Navarro, Maribel, Chiara Gabbiani, Luigi Messori y Dinorah Gambino. "Metal-based drugs for malaria, trypanosomiasis and leishmaniasis: recent achievements and perspectives". Drug Discovery Today 15, n.º 23-24 (diciembre de 2010): 1070–78. http://dx.doi.org/10.1016/j.drudis.2010.10.005.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
45

Sales, Prandi, Castro, Leal, Cunha, Kuca y Ramalho. "Recent Developments in Metal-Based Drugs and Chelating Agents for Neurodegenerative Diseases Treatments". International Journal of Molecular Sciences 20, n.º 8 (12 de abril de 2019): 1829. http://dx.doi.org/10.3390/ijms20081829.

Texto completo
Resumen
The brain has a unique biological complexity and is responsible for important functions in the human body, such as the command of cognitive and motor functions. Disruptive disorders that affect this organ, e.g. neurodegenerative diseases (NDDs), can lead to permanent damage, impairing the patients’ quality of life and even causing death. In spite of their clinical diversity, these NDDs share common characteristics, such as the accumulation of specific proteins in the cells, the compromise of the metal ion homeostasis in the brain, among others. Despite considerable advances in understanding the mechanisms of these diseases and advances in the development of treatments, these disorders remain uncured. Considering the diversity of mechanisms that act in NDDs, a wide range of compounds have been developed to act by different means. Thus, promising compounds with contrasting properties, such as chelating agents and metal-based drugs have been proposed to act on different molecular targets as well as to contribute to the same goal, which is the treatment of NDDs. This review seeks to discuss the different roles and recent developments of metal-based drugs, such as metal complexes and metal chelating agents as a proposal for the treatment of NDDs.
Los estilos APA, Harvard, Vancouver, ISO, etc.
46

Wedlock, Louise E. y Susan J. Berners-Price. "Recent Advances in Mapping the Sub-cellular Distribution of Metal-Based Anticancer Drugs". Australian Journal of Chemistry 64, n.º 6 (2011): 692. http://dx.doi.org/10.1071/ch11132.

Texto completo
Resumen
There are increasing reports of novel metal-based chemotherapeutics that have either improved cancer cell selectivity, or alternative mechanisms of action, to existing anticancer drugs, and techniques are required for determining their sub-cellular molecular targets. Imaging methods offer many distinct advantages over destructive fractionation techniques, including the preservation of useful morphological information; however, mapping the intracellular distribution of metal ions inside tumour cells still remains challenging. Recent advances in three modes of imaging are discussed in this review, with a particular focus on the application to metal-based cancer chemotherapy – fluorescence microscopy, electron microscopy (including energy-filtered transmission electron microscopy (EFTEM)), and a new technique, Nano-scale secondary ion mass spectrometry (NanoSIMS).
Los estilos APA, Harvard, Vancouver, ISO, etc.
47

Cao, Jian, Xuejiao Li y Hongqi Tian. "Metal-Organic Framework (MOF)-Based Drug Delivery". Current Medicinal Chemistry 27, n.º 35 (29 de octubre de 2020): 5949–69. http://dx.doi.org/10.2174/0929867326666190618152518.

Texto completo
Resumen
Background: Developing a controllable drug delivery system is imperative and important to reduce side effects and enhance the therapeutic efficacy of drugs. Metal-organic frameworks (MOFs) an emerging class of hybrid porous materials built from metal ions or clusters bridged by organic linkers have attracted increasing attention in the recent years owing to the unique physical structures possessed, and the potential for vast applications. The superior properties of MOFs, such as well-defined pore aperture, tailorable composition and structure, tunable size, versatile functionality, high agent loading, and improved biocompatibility, have made them promising candidates as drug delivery hosts. MOFs for drug delivery is of great interest and many very promising results have been found, indicating that these porous solids exhibit several advantages over existing systems. Objective: This review highlights the latest advances in the synthesis, functionalization, and applications of MOFs in drug delivery, and has classified them using drug loading strategies. Finally, challenges and future perspectives in this research area are also outlined.
Los estilos APA, Harvard, Vancouver, ISO, etc.
48

ABRAR UL HASSAN, Nyiang Kennet Nkungli y C. Guleryuz. "COMPUTATIONAL DESIGNING OF DEFERIPRONE BASED NOVEL DRUGS AS EFFICIENT ANTI-PARKINSON AGENTS". Latin American Applied Research - An international journal 53, n.º 2 (8 de febrero de 2023): 157–62. http://dx.doi.org/10.52292/j.laar.2023.986.

Texto completo
Resumen
Comprehensive and detailed density functional theory (DFT) computations are done herein at the M05-2X/6-31G(d) level of theory to scrutinize the interactions of Fe3+ ions with computationally designed deferiprone (DFP)-based novel complexing drugs. The thermodynamic properties of metal-deferiprone complexes were determined in water as solvent. The theoretical binding energy trend indicated that [Fe(DrugC)3] has the highest interaction affinity. Natural bond orbital (NBO) analysis was used to estimate and assess atomic natural charges, the charge transfer between metal ions with ligands (oxygen atoms), and the interaction energy (E(2)) levels. The determined value of E(2) (donor-acceptor interaction energy) for the [Fe(DrugC)3] complex was found to be greater than those of the other complexes. The understudy novel chelators were made to interact with graphidyne based nanosheet to understand their adsorption behavior. Interestingly, ?---CH interaction of the complexes with the nanosheet were found around (2.41-3.12A), which endorsed their good behavior. The quantum theory of atoms in molecules (QTAIM) analysis was used to establish the type of efficient interactions and bonding characteristics in water. On the basis of the QTAIM results, [Fe(DrugC)3] was found to have the strongest M-O bond. The M-O bonds in the compounds were non-covalent, whereas they were electrostatic or partially covalent in all other complexes.
Los estilos APA, Harvard, Vancouver, ISO, etc.
49

Dantas, Kele Cristina Ferreira, Jânia dos Santos Rosário y Priscila Pereira Silva-Caldeira. "Polymeric Nanosystems Applied for Metal-Based Drugs and Photosensitizers Delivery: The State of the Art and Recent Advancements". Pharmaceutics 14, n.º 7 (20 de julio de 2022): 1506. http://dx.doi.org/10.3390/pharmaceutics14071506.

Texto completo
Resumen
Nanotechnology-based approaches for targeting the delivery and controlled release of metal-based therapeutic agents have revealed significant potential as tools for enhancing the therapeutic effect of metal-based agents and minimizing their systemic toxicities. In this context, a series of polymer-based nanosized systems designed to physically load or covalently conjugate metal-based therapeutic agents have been remarkably improving their bioavailability and anticancer efficacy. Initially, the polymeric nanocarriers were applied for platinum-based chemotherapeutic agents resulting in some nanoformulations currently in clinical tests and even in medical applications. At present, these nanoassemblies have been slowly expanding for nonplatinum-containing metal-based chemotherapeutic agents. Interestingly, for metal-based photosensitizers (PS) applied in photodynamic therapy (PDT), especially for cancer treatment, strategies employing polymeric nanocarriers have been investigated for almost 30 years. In this review, we address the polymeric nanocarrier-assisted metal-based therapeutics agent delivery systems with a specific focus on non-platinum systems; we explore some biological and physicochemical aspects of the polymer–metallodrug assembly. Finally, we summarize some recent advances in polymeric nanosystems coupled with metal-based compounds that present potential for successful clinical applications as chemotherapeutic or photosensitizing agents. We hope this review can provide a fertile ground for the innovative design of polymeric nanosystems for targeting the delivery and controlled release of metal-containing therapeutic agents.
Los estilos APA, Harvard, Vancouver, ISO, etc.
50

Biegański, Przemysław, Łukasz Szczupak, Manuel Arruebo y Konrad Kowalski. "Brief survey on organometalated antibacterial drugs and metal-based materials with antibacterial activity". RSC Chemical Biology 2, n.º 2 (2021): 368–86. http://dx.doi.org/10.1039/d0cb00218f.

Texto completo
Resumen
Recent developments in the field of organometalated antibacterial drugs and metal-based materials with antibacterial activity are reviewed. They emerge as attractive candidates for combating pathogenic bacteria including drug resistant strains.
Los estilos APA, Harvard, Vancouver, ISO, etc.
Ofrecemos descuentos en todos los planes premium para autores cuyas obras están incluidas en selecciones literarias temáticas. ¡Contáctenos para obtener un código promocional único!

Pasar a la bibliografía